Bristol Myers Squibb Acquires Karuna Therapeutics for $14 Billion, Boosting Neuroscience Portfolio

[ad_1] NEW YORK (AP) — Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal. Bristol Myers Squibb…

Biotech stocks that could surge more than 35% include one name targeting treatments for schizophrenia

[ad_1] With new drug launches and product approvals on the horizon, some biotechnology stocks could finally be due for a breakout, market participants say. Biotech investors could use a break.…